原发性IgA肾病的治疗进展

原发性IgA肾病是最普遍的原发性肾小球肾炎，其病理特点为IgA沉积在肾小球系膜细胞区。随着对原发性IgA肾病的逐渐认识，发现其并不是一种良性肾脏疾病，大约在20年内，30%~40%的原发性IgA肾病发展至终末期肾病，需要肾脏替代治疗。因此，原发性IgA肾病需要有效精准的治疗延缓疾病进展。本文主要对原发性IgA肾病治疗的相关研究进行综述，发现目前支持治疗成为原发性IgA肾病的主要治疗方式，另外扁桃体切除、激素、免疫抑制剂等治疗方式在一定情况下也可以用于原发性IgA肾病的治疗，近年来又出现了多种新型治疗方法为原发性IgA肾病的治疗提供了更多选择。

Advances in the Treatment of Primary IgA Nephropathy

Primary IgA nephropathy is the most common type of primary glomerulonephritis，with pathological features of mesangial deposition of IgA. With increasingly intensive understanding of primary IgA nephropathy，it is found that it is not a benign kidney disease. In about 20 years，30%-40% of primary IgA nephropathy develops into end-stage renal disease，requiring kidney replacement therapy. Therefore，primary IgA nephropathy needs effective and precise treatment to delay its progression. This article mainly reviews the advances in the treatment of primary IgA nephropathy：supportive therapy has become the main treatment. Besides，tonsillectomy，hormone therapy，immunosuppressive therapy and other treatments can be used under certain circumstances. Recently emerged treatments can also be used as treatment options for choice.